(Q38073792)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23316711%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

review article

1 reference

title

Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23316711%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23316711%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Andreas Plückthun

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23316711%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Manuel Simon

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23316711%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Uwe Zangemeister-Wittke

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23316711%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

14 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23316711%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Delivery

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23316711%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23316711%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23316711%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

451-468

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23316711%20AND%20SRC:MED&resulttype=core&format=json

Antibody-drug conjugates for cancer therapy

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Immunotoxin treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Engineering novel binding proteins from nonimmunoglobulin domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

In vitro selection of RNA molecules that bind specific ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Aptamers for Targeted Drug Delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Frequent EpCam protein expression in human carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Nuclear signalling by tumour-associated antigen EpCAM

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Initial activation of EpCAM cleavage via cell-to-cell contact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Cancer stem cells: models and concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Detection, clinical relevance and specific biological properties of disseminating tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

EpCAM (CD326) finding its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Epithelial cell adhesion molecule expression (CD326) in cancer: a short review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

The biology of the 17-1A antigen (Ep-CAM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

The emerging role of EpCAM in cancer and stem cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

The structural analysis of adhesions mediated by Ep-CAM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

ErbB receptors and signaling pathways in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Sustained and cancer cell targeted cytosolic delivery of Onconase results in potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

DARPins and other repeat protein scaffolds: advances in engineering and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

High-affinity binders selected from designed ankyrin repeat protein libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Designed ankyrin repeat proteins (DARPins) from research to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Cell-specific aptamer-mediated targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

In vivo selection of tumor-targeting RNA motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Generating aptamers for recognition of virus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Arming antibodies: prospects and challenges for immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Antibody-drug conjugates: targeted drug delivery for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Investigational antibody drug conjugates for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Antibody-maytansinoid conjugates designed to bypass multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Secreted and tumour targeted human carboxylesterase for activation of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Mechanisms of resistance to TRAIL-induced apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Cellular uptake of ribonuclease A relies on anionic glycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Chemotherapy and radiotherapy for mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Drug delivery systems: entering the mainstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

A nonviral carrier for targeted gene delivery to tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938

EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.759938